The Assign Group to Standardize with Oracle Apps
Oracle reports that The Assign Group, a CRO based in Austria, has selected Oracle Health Sciences apps to streamline clinical data and clinical trial management across its network of European and South American affiliates.
Oracle Clinical, Oracle Remote Data Capture, Oracle Adverse Event Reporting System, and Oracle Thesaurus Management System will serve as the foundation of the Group's new data management infrastructure, and Oracle’s Siebel Clinical Trial Management System will serve as its centralized database for managing clinical trial processes.
Factors behind the decision included the CRO's desire for an off-the-shelf solution that would allow them to focus on business rather than IT systems, according to a company press release.
“Health sciences organizations like The Assign Group are increasingly looking to IT solutions to help streamline clinical data management and improve efficiency throughout the clinical trial process,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
